Posted on September 23rd, 2011 by
Cardio3 BioSciences—which develops regenerative and protective therapies for the treatment of heart disease—hopes the new subsidiary will support its clinical and development activities in the United States and bolster existing ties with Mayo Clinic. Belgium-based biotechnology company Cardio3 BioSciences announced Thursday that it has established a subsidiary in Rochester of the same name.
Twin Cities Business, 9/23/11
You must be logged-in to the site to post a comment.